That is misleading. It is not an 18% reduction. It is an 18% reduction vs the placebo. They are currently already on the current standard of care, and this is outperforming that. If a drug outperforms standard of care, that is a very positive result!
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-33
-
- There are more pages in this discussion • 595 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.010(2.27%) |
Mkt cap ! $247.7M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 45.5¢ | 43.5¢ | $334.2K | 743.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 129191 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 153901 | 9 |
View Market Depth
| Last trade - 13.06pm 15/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |